The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

We're trying to set the stage for integrating these ideas" Anthony Vella, professor and Boehringer Ingelheim Chair in ...

Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with ...

Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G ...

The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, one of the world's ...

Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of ...

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...